Solution reagent kit AmpliSeq™

blood sampleNGSfor DNA analysis

The Myeloid Panel enables concurrent analysis of both DNA and RNA from blood and bone marrow samples in a single assay to study biomarkers associated with hematologic malignancies. The panel covers relevant targets for these major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Key features include: Key features High-value content - Targets biomarkers across 69 genes including challenging targets such as CEBPA and FLT3-ITDs Fast, streamlined workflow - Prepare sequencing-ready libraries in a single day from as little as 10 ng high-quality DNA and RNA Accurate data - Detect somatic mutations down to 5% frequency using local or cloud-based analysis The Myeloid Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS), NGS technology, and automated analysis. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels. Specifications Assay time - 5.5 – 7.5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) Cancer type - Hematologic Content specifications - Targets biomarkers across 69 genes (40 key DNA target genes, 29 RNA fusion driver genes, and 5 gene expression levels) Description - Targeted panel to study 40 DNA genes, 29 RNA fusion driver genes, and 5 gene expression levels associated with myeloid cancers. Hands-on time - < 1.5 hr